Mylan Launches Generic Frova
Frova, a selective 5-HT1B/1D receptor agonist, is indicated to treat acute migraine headaches with or without aura in adult patients. It binds with high affinity to 5-HT1B/1D receptors. The therapeutic activity of frovatriptan is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
Frovatriptan Succinate Tablets are available as a 2.5mg strength.
For more information call (800) RX-MYLAN or visit Mylan.com.